Progresses in nucleic acid testing for COVID-19.

Kangsheng Liu, Zhirong Xu, Xiaodong Mao, Taiping Li, Juan Wen

Abstract readReview

In one paragraph

Review in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Glycan Nanostructures of Human Coronaviruses.International journal of nanomedicine · 2021
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kangsheng LiuDepartment of Clinical Laboratory, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital Nanjing 210029, China.

Zhirong XuDepartment of Clinical Laboratory, The First Affiliated Hospital of Soochow University Suzhou 215006, China.

Xiaodong MaoDepartment of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210028, China.

Taiping LiDepartment of Neuro-Psychiatric Institute, Nanjing Medical University Affiliated Brain Hospital Nanjing 210029, China.

Juan WenNanjing Maternity and Child Health Care Institute, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital Nanjing 210004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 (Coronavirus disease 2019) epidemic has rapidly spread since its outbreak. By 24:00, July 19, China had reported 83,682 confirmed infectious cases of COVID-19, including 4,634 deaths. The prevention and control of COVID-19 remains extremely urgent. Owing to its strong infectivity and onset in populations, early detection of infectious cases of COVID-19 is of great significance to control the epidemic. Nevertheless, clinical experiences in nucleic acid testing (NAT) are limited. False negative results of NAT inconsistent with clinical diagnosis are often reported. Therefore, it is necessary to improve the sensitivity and specificity of NAT. This study aims to summarize the current situation and prospect of NAT application based on the lasted findings on COVID-19 infection. Meanwhile, potential methods are proposed to improve the validity of NAT, like improving sample quality. The review may provide references for clinical and experimental explorations on COVID-19.

Indexed as

COVID-19NATpathogenesisquality controlresults interpretation

Identifiers

PMID33194071

PMCPMC7653635

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.